Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 2Mesothelioma 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Turcot syndrome 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelin-positive Advanced Refractory Solid Tumors 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Advanced Solid Tumor 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × fludarabine phosphate × Other solid neoplasm × Clear all
NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Recruiting
351 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡